Truvada archivos - Fundación GEP

Gilead forced to withdraw Truvada® patent application in Argentina

The decision, for which the Fundación GEP contributed with/to decisive arguments, paves the way to generic versions to facilitate access to treatments. Por: Julia Varela May 23, 2017 - In a resolution that means a step forward in safeguarding the right to health, Argentina’s patent office (the National Institute of Industrial Property - INPI) forced

Argentina could save U$11M per year buying generic version of Truvada®

Fundación GEP2015-11-04T20:01:06-03:00miércoles, 4 noviembre, 2015|Access to Medicines, Advocacy, Health Safeguards, Intellectual Property, Patent opposition|

The Argentine Community of People Living with HIV requested the rejection of a patent for an essential HIV/AIDS medicine. If the Argentine Patent Office does grant the this request, Argentina could produce generic versions at a lower cost representing a potential saving of over US$11 million. Argentina April 13th, 2015.- The Grupo Efecto Positivo Foundation (FGEP) in collaboration with the Argentine